ClinicalTrials.gg
CompletedNCT03478644Updated Oct 15, 2018Results posted

Oral and Dermal Tolerability Clinical Study of an Experimental Denture Wipe

An interventional study of Experimental Denture Wipe and Tap Water in Denture Cleansers, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-15.

Sponsored by GlaxoSmithKline · Not applicable, Interventional, and Device feasibility

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Oct 2016, registered Mar 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this two-phase study was to evaluate the oral and dermal tolerance of an experimental, non-rinse denture cleansing wipe after 7 and 14 days of use. In addition, the consumer acceptability of the denture cleansing wipes was also evaluated via a consumer acceptability questionnaire. A methodology was also evaluated to assess the efficacy of the denture wipe at removing food debris as exploratory objective.

Read the detailed description

This was a two phase single-center study. Phase 1 (Food removal testing), was monadic and only the wipe treatment was administered to complete upper dentures. Phase 1 participants then progressed to phase 2 (oral soft tissue [OST] and dermal assessment) which was an examiner blind parallel group, randomized and stratified (by denture type) design where both treatments (a single wipe and water control) were administered. Phase 2 participants included both fully and partially edentulous adult participants. Participants were not permitted to use any denture cleansers other than those provided and were not permitted to use denture fixatives for the duration of the study. The study comprised a Screening/Baseline visit and a 2 week Treatment Period with visits after 1 and 2 weeks use. Following screening participants who were eligible for Phase 1 were assessed for food migration adequacy. Participants consumed 30-32g (gram) of non-salted peanut halves in a controlled manner, then briefly rinsed their mouth with water and removed their upper denture. The investigator visually assessed the peanut particle migration underneath the denture on a 0-3 scale and those participants with a score greater than 0 were wiped by the participant with the experimental denture wipe. The mass of peanuts removed by the wipe and those remaining on the denture was subsequently measured. For a subset of participants (2 participants per peanut particle migration scale score), their dentures were photographed after peanut consumption both before and after use of the experimental denture wipe. Phase 1 participants then continued into Phase 2. All Phase 2 participants undertook an OST examination and a dermatological assessment of both sides of their lead hand, then randomized. The dental examiner and dermatologist were blinded to the treatment allocation. The results of these assessments served as the baseline reading. Participants were then instructed on the use of their assigned treatment with the first application undertaken and supervised at the study site. Participants were provided with a diary card to record their treatment applications and a consumer acceptability questionnaire to be completed at the time of their first at home treatment use. Participants were also provided with denture cleansing tablets for use overnight for the duration of the study in order to maintain denture hygiene. Participants returned to the study site after 7±3 and 14±3 days use of product for repeat OST and dermatological assessments.

02

Conditions studied

  • Denture Cleansers
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Demonstrated understanding of the study procedures, restrictions and was willing to participate as evidenced by voluntary written and had received a signed and dated copy of the informed consent form.
  • Understood and was willing, able and comply with all study procedures and restrictions.
  • Participant was in good general and mental health with, in the opinion of the investigator or medically qualified designee - (a) no and relevant abnormalities of medical or physical history; (b) absence of any condition that impacted on the participant's safety or well-being or affected the individual's ability to understand and follow study procedures.
  • Denture Requirements, fully or partially edentulous: (a) Phase 1 eligible participants had a full upper denture and may Have a full or partial lower denture or no lower Denture; (b) Phase 2 eligible subjects will have at least one full or partial denture; (c) Dentures considered in good condition according to the investigator or dental examiner, with no damage according to assessment criteria; (d) Participants with a peanut particle migration rating greater than zero on the upper denture only for participants screened for food removal testing.
  • Skin Phototype (Fitzpatrick), I to IV, according to the scale only skin phototypes I to IV are acceptable for inclusion in this study: Type I - White; very fair; freckles; typical albino skin. Always burns, never tans, Type II -White; fair. Usually burns, tans with difficulty, Type III - Beige; very common. Sometimes mild burn, gradually tans to a light brown, Type IV - Beige with a brown tint; typical Mediterranean Caucasian skin. Rarely burns, tans with ease to a moderate brown, Type V - Dark brown. Very rarely burns, tans very easily, Type VI Black - Never burns, tans very easily, deeply pigmented.

Exclusion criteria

Exclusion Criteria:

  • Women who were known to be pregnant or who were intending to become pregnant over the duration of the study.
  • Women who were breast-feeding.
  • Known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients. Known allergy to any nuts or peanuts. History of allergic reactions or intense feelings of discomfort to topically used products: cosmetics or drugs.
  • Participation in another clinical study (including cosmetic studies) or receipt of an drug within 30 days of the screening visit, except for participants who were enrolled on GSKCH study 205915 who might enrolled onto this study 7 days after their completion of 205915. Previous participation in this study.
  • Recent history (within the last one year) of alcohol or other substance abuse.
  • An employee of the sponsor or the study site or members of their immediate family.
  • Denture adhesive users were excluded from this study.
  • Participants with OST findings such as, stomatitis, open sores, lesions, redness or swelling were excluded.
  • Other Conditions because of participants were excluded are as follows: History of swallowing or choking difficulties; participants unwilling to refrain from using their existing denture cleansing routine for the duration of the study; taking or have taken a bisphosphonate drug for treatment of osteoporosis; skin marks in the experimental area which may interfere with the evaluation of potential skin reactions; active skin diseases (local and/or disseminated) that may interfere with the study results; participants with immunodeficiencies, intense sunlight exposure or tanning session within 15 days before the baseline evaluation or during the study that has resulted in sunburn; body cosmetic and/or dermatological treatment until three weeks before screening or during the study; continual use of therapeutic, topical or systemic use of the following drugs: , antihistamines, non-steroidal anti-inflammatory drugs and within two weeks before the screening for chronic conditions; oral or topical treatment with vitamin A acid and/or its derivatives within one month before start of study; vaccination within three weeks before or during the study; participants with dermographism; any condition not previously mentioned that in the investigator's opinion may impair the study evaluation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Experimental Denture Wipe

    Participants of this arm were instructed to use the experimental wipe to clean their dentures up to 4 times daily.

    Device: Experimental Denture Wipe

  • Placebo comparator
    Tap Water

    Participants of this arm were instructed to use running tap water to clean their dentures up to 4 times daily.

    Other: Tap Water

Interventions

  • DeviceExperimental Denture Wipe

    Participants were instructed to use the experimental wipe to clean their dentures, external to their mouth, up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days. Participants were instructed to use one wipe per denture.

  • OtherTap Water

    Participants were instructed to use running tap water to clean their dentures up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Experiencing or Reporting Treatment Emergent (TE) Oral Adverse Events (AEs) on or Before 14 Days of Use

    Proportion of participants experiencing or reporting TE oral AEs on or before 14 days of use treatments were reported. TE AEs include AEs that were identified during an oral soft tissue examination, a dermal assessment or reported by the subject. AEs were categorized as oral or non-oral by the Clinical Research scientist prior to database lock (oral AE's were AEs effecting tissues associated with the oral cavity extending from the labial mucosa to the pharyngeal area).

    Time frame: up to 14 days

  2. Proportion of Participants Experiencing or Reporting Treatment Emergent (TE) Oral Adverse Events (AEs) on or Before 7 Days of Use

    Proportion of participants experiencing or reporting TE oral AEs on or before 7 days of use treatments were reported. TE AEs include AEs that were identified during an oral soft tissue examination, a dermal assessment or reported by the subject. AEs were categorized as oral or non-oral by the Clinical Research scientist prior to database lock (oral AE's were AEs effecting tissues associated with the oral cavity extending from the labial mucosa to the pharyngeal area).

    Time frame: up to 7 days

Secondary outcomes

  1. Proportion of Participants Experiencing Skin Irritation Scores of 2 or Greater After 7 and 14 Days of Use

    Dermal assessment performed by a suitably qualified dermatologist on the front and back of the participant's dominant hand (hand with which participant used to hold the wipe during use) using skin irritation score that range from 0-4 as follows: 0 = no apparent cutaneous involvement, 0.5= equivocal reaction, 1= slight erythema with or without oedema, 2= moderate erythema, oedema with or without papules, 3= severe erythema, oedema with or without papules, 4= severe erythema, oedema with vesicles or blisters. Any site where skin irritation was scored ≥2, was visually assessed and reported.

    Time frame: Day 7, Day 14

  2. Number of Participants Responses for Consumer Acceptability Questionnaire Score

    All the participants supplied with a consumer acceptability questionnaire (Question \[Q\] 1 to 4) to complete immediately before \& after their first use of treatment at home after eating a meal. The number of participants with individual score was reported. After eating \& before cleaning denture: Q1= how fresh does denture feel?, Q2= how clean does denture feel?; Look in the mirror and smile, now answer the following questions: Q3= after eating \& before cleaning, how clean does denture/smile look ?, Q4= after removing \& cleaning denture, how fresh does denture feel?, Q5= after removing \& cleaning denture, run your tongue over denture teeth, how clean does denture feel?, Q6= after removing \& cleaning denture, how clean does denture/smile look?, Q7= after removing \& cleaning denture, how satisfied are you with amount of debris removed? All questions were scored as follows for respective parameter(fresh/clean/satisfied): 0=Not at all, 1=slightly, 2=moderately, 3=very, 4=extremely.

    Time frame: Day 7

07

Results

Posted Aug 31, 2018

Participant flow

All participants were recruited at one center in the United States.

Phase 1
Participant flow — Phase 1
MilestoneExperimental Denture WipeWater Rinse
Started310
Completed310
Not completed00
Phase 2
Participant flow — Phase 2
MilestoneExperimental Denture WipeWater Rinse
Started7676
Completed7375
Not completed31
Withdrew: Withdrawal by subject21
Withdrew: Lost to follow-up10

Outcome measures

PrimaryProportion of Participants Experiencing or Reporting Treatment Emergent (TE) Oral Adverse Events (AEs) on or Before 14 Days of Use

Proportion of participants experiencing or reporting TE oral AEs on or before 14 days of use treatments were reported. TE AEs include AEs that were identified during an oral soft tissue examination, a dermal assessment or reported by the subject. AEs were categorized as oral or non-oral by the Clinical Research scientist prior to database lock (oral AE's were AEs effecting tissues associated with the oral cavity extending from the labial mucosa to the pharyngeal area).

Time frame:
up to 14 days
Reported as:
Number · Proportion of participants
Proportion of Participants Experiencing or Reporting Treatment Emergent (TE) Oral Adverse Events (AEs) on or Before 14 Days of Use
Proportion of participantsExperimental Denture WipeWater Rinse
Proportion of Participants Experiencing or Reporting Treatment Emergent (TE) Oral Adverse Events (AEs) on or Before 14 Days of Use0.039 (0.01 to 0.11)0.013 (0.00 to 0.07)
PrimaryProportion of Participants Experiencing or Reporting Treatment Emergent (TE) Oral Adverse Events (AEs) on or Before 7 Days of Use

Proportion of participants experiencing or reporting TE oral AEs on or before 7 days of use treatments were reported. TE AEs include AEs that were identified during an oral soft tissue examination, a dermal assessment or reported by the subject. AEs were categorized as oral or non-oral by the Clinical Research scientist prior to database lock (oral AE's were AEs effecting tissues associated with the oral cavity extending from the labial mucosa to the pharyngeal area).

Time frame:
up to 7 days
Reported as:
Number · Proportion of participants
Proportion of Participants Experiencing or Reporting Treatment Emergent (TE) Oral Adverse Events (AEs) on or Before 7 Days of Use
Proportion of participantsExperimental Denture WipeWater Rinse
Proportion of Participants Experiencing or Reporting Treatment Emergent (TE) Oral Adverse Events (AEs) on or Before 7 Days of Use0.013 (0.00 to 0.07)0.000 (0.00 to 0.05)
SecondaryProportion of Participants Experiencing Skin Irritation Scores of 2 or Greater After 7 and 14 Days of Use

Dermal assessment performed by a suitably qualified dermatologist on the front and back of the participant's dominant hand (hand with which participant used to hold the wipe during use) using skin irritation score that range from 0-4 as follows: 0 = no apparent cutaneous involvement, 0.5= equivocal reaction, 1= slight erythema with or without oedema, 2= moderate erythema, oedema with or without papules, 3= severe erythema, oedema with or without papules, 4= severe erythema, oedema with vesicles or blisters. Any site where skin irritation was scored ≥2, was visually assessed and reported.

Time frame:
Day 7, Day 14
Reported as:
Number · Proportion of participants
Proportion of Participants Experiencing Skin Irritation Scores of 2 or Greater After 7 and 14 Days of Use
Proportion of participantsExperimental Denture WipeWater Rinse
At Day 700
At Day 1400
SecondaryNumber of Participants Responses for Consumer Acceptability Questionnaire Score

All the participants supplied with a consumer acceptability questionnaire (Question \[Q\] 1 to 4) to complete immediately before \& after their first use of treatment at home after eating a meal. The number of participants with individual score was reported. After eating \& before cleaning denture: Q1= how fresh does denture feel?, Q2= how clean does denture feel?; Look in the mirror and smile, now answer the following questions: Q3= after eating \& before cleaning, how clean does denture/smile look ?, Q4= after removing \& cleaning denture, how fresh does denture feel?, Q5= after removing \& cleaning denture, run your tongue over denture teeth, how clean does denture feel?, Q6= after removing \& cleaning denture, how clean does denture/smile look?, Q7= after removing \& cleaning denture, how satisfied are you with amount of debris removed? All questions were scored as follows for respective parameter(fresh/clean/satisfied): 0=Not at all, 1=slightly, 2=moderately, 3=very, 4=extremely.

Time frame:
Day 7
Reported as:
Count of participants · Participants
Number of Participants Responses for Consumer Acceptability Questionnaire Score
ParticipantsExperimental Denture WipeWater Rinse
Q1: Score 0 - Not fresh at all2018
Q1: Score 1 - Slightly fresh1626
Q1: Score 2 - Moderately fresh1817
Q1: Score 3 - Very fresh1410
Q1: Score 4 - Extremely fresh85
Q2: Score 0 - Not clean at all1212
Q2: Score 1 - Slightly clean1223
Q2: Score 2 - Moderately clean2621
Q2: Score 3 - Very clean1514
Q2: Score 4 - Extremely clean116
Q3: Score 0 - Not clean at all51
Q3: Score 1 - Slightly clean1515
Q3: Score 2 - Moderately clean2331
Q3: Score 3 - Very clean2321
Q3: Score 4 - Extremely clean108
Q4: Score 0 - Not fresh at all00
Q4: Score 1 - Slightly fresh03
Q4: Score 2 - Moderately fresh1122
Q4: Score 3 - Very fresh3231
Q4: Score 4 - Extremely fresh3320
Q5: Score 0 - Not clean at all01
Q5: Score 1 - Slightly clean10
Q5: Score 2 - Moderately clean918
Q5: Score 3 - Very clean3237
Q5: Score 4 - Extremely clean3420
Q6: Score 0 - Not clean at all00
Q6: Score 1 - Slightly clean11
Q6: Score 2 - Moderately clean1018
Q6: Score 3 - Very clean3337
Q6: Score 4 - Extremely clean3220
Q7: Score 0 - Not satisfied at all00
Q7: Score 1 - Slightly satisfied00
Q7: Score 2 - Moderately satisfied921
Q7: Score 3 - Very satisfied4036
Q7: Score 4 - Extremely satisfied2719

Adverse events

Collected over Approximately 17 days (from Screening Visit to Visit 3). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Denture Wipe0/76 (0%)0/76 (0%)3/76 (3.9%)
Water Rinse0/76 (0%)0/76 (0%)1/76 (1.3%)
Most frequent other events
Most frequent other events
EventExperimental Denture WipeWater Rinse
Mouth InjuryInjury, poisoning and procedural complications2/760/76
Lip InjuryInjury, poisoning and procedural complications1/760/76
Tongue coatedGastrointestinal disorders0/761/76

Baseline characteristics

Baseline assessment was performed on safety population, which included all participants who were randomized and received treatment at least once during the study.

Age, Continuous
Age, Continuous(years)Experimental Denture WipeWater RinseTotal
Mean60.99 ± 12.70261.03 ± 12.62261.01 ± 12.620
Sex: Female, Male
Sex: Female, Male(Participants)Experimental Denture WipeWater RinseTotal
Female5748105
Male192847
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental Denture WipeWater RinseTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander101
Black or African American10818
White6467131
More than one race101
Unknown or Not Reported000
08

Study locations

1 site
  • GSK Investigational Site
    Fort Wayne, Indiana 46825, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2016 to primary completion in Oct 2016, 0 months.

Results were first posted in Aug 2018, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2018
First posted
Mar 27, 2018
StartActual
Oct 10, 2016
Primary completionActual
Oct 31, 2016
CompletionActual
Oct 31, 2016
Results first posted
Aug 31, 2018
Last update
Oct 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03478644
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 27, 2018
Start date
Oct 10, 2016
Primary completion
Oct 31, 2016
Completion
Oct 31, 2016
Results posted
Aug 31, 2018
Last update
Oct 15, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion